PDCD1 and hereditary sensory and autonomic neuropathy: The Keynote-001 trial, for instance, identified a heightened incidence of CIP of all grades among patients treated with a PD-1 inhibitor (pembrolizumab) who had previously undergone radiotherapy, as compared to those who hadn’t (13% vs. 1%, p < 0.05) [45].